Home Newsfeeds Aurora Innovation CEO Says Don’t Have Any Fixed Plans To Raise Capital

Aurora Innovation CEO Says Don’t Have Any Fixed Plans To Raise Capital

-Reuters At Goldman Sachs Tech Conference

byBenzinga Newsdesk

September 15, 2022

1 minute read

-Reuters At Goldman Sachs Tech Conference

Sanofi Late-Breaking Amlitelimab Phase 2b Data Presented At EADV Show Potential Best-In-Class Profile In Atopic Dermatitis; Clinically Meaningful Improvements Were Seen In All Key Secondary Endpoints At Week 16 With Continued Improvements Through Week…

By Benzinga Newsdesk

October 13, 10:03 AM

Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitisPatients treated with amlitelimab experienced up to 61.5% improvement in average Eczema Area and Severity

SNY

News

‘Yumanity Therapeutics Patent App #20220298168 Published For “Compounds Useful In The Treatment Of Neurological Disorders” Target Alzheimer’s’ – U.S. Patent & Trademark Office

By Benzinga Newsdesk

September 28, 12:39 PM

https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=20220298168&OS=20220298168&RS=20220

YMTX

$100 Invested In Southern Copper 20 Years Ago Would Be Worth This Much Today

By Benzinga Insights

August 4, 11:11 AM

Southern Copper (NYSE:SCCO) has outperformed the market over the past 20 years by 8.61% on an annualized basis producing an average annual return of 16.58%. Currently, Southern Copper has a market capitalization of $35.92 billion.

SCCO

Gossamer Bio Q2 EPS $(0.74) Up From $(0.80) YoY

By Benzinga Newsdesk

August 9, 8:19 AM

Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.74) per share. This is a 7.5 percent increase over losses of $(0.80) per share from the same period last year.

GOSS

Aurora Innovation CEO Says Don’t Have Any Fixed Plans To Raise Capital

Related Posts

Sanofi Late-Breaking Amlitelimab Phase 2b Data Presented At EADV Show Potential Best-In-Class Profile In Atopic Dermatitis; Clinically Meaningful Improvements Were Seen In All Key Secondary Endpoints At Week 16 With Continued Improvements Through Week…

‘Yumanity Therapeutics Patent App #20220298168 Published For “Compounds Useful In The Treatment Of Neurological Disorders” Target Alzheimer’s’ – U.S. Patent & Trademark Office

$100 Invested In Southern Copper 20 Years Ago Would Be Worth This Much Today

Gossamer Bio Q2 EPS $(0.74) Up From $(0.80) YoY